Haier Biomedical Reports 31.6% Decline in 2025 Net Profit Attributable to Owners

Stock News02-27

Qingdao Haier Biomedical Co.,Ltd. (688139.SH) has released its preliminary financial results for the year 2025. The company achieved operating revenue of 2.33 billion yuan, representing a year-on-year increase of 2.0%. However, net profit attributable to owners of the parent company was 250 million yuan, marking a decrease of 31.6% compared to the previous year.

In 2025, the company's overseas revenue reached 840 million yuan, a significant increase of 17.9% year-on-year. This segment's contribution to the company's primary business revenue reached a new high of 36%, up by 5 percentage points from 2024. Growth was observed across all regions: Europe grew by 16.0%, the Asia-Pacific region by 26.0%, the Americas by 12.2%, and Africa by 17.8%.

Conversely, domestic revenue for 2025 was 1.47 billion yuan, a decline of 5.5% compared to the previous year. Revenue from new industries accounted for 48.5% of the total, with a growth rate of 8.8%. The low-temperature storage industry segment contributed 51.5% of revenue, experiencing a decline of 3.9% year-on-year. Following a return to positive growth in the third quarter, the growth rate accelerated in the fourth quarter, indicating a gradual recovery from the bottom.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1107989005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 16:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1107989005","market":"sh","top_or_hot":-1,"title":"Haier Biomedical Reports 31.6% Decline in 2025 Net Profit Attributable to Owners","media":"Stock News","content":"<p>Qingdao Haier Biomedical Co.,Ltd. (688139.SH) has released its preliminary financial results for the year 2025. The company achieved operating revenue of 2.33 billion yuan, representing a year-on-year increase of 2.0%. However, net profit attributable to owners of the parent company was 250 million yuan, marking a decrease of 31.6% compared to the previous year.</p>\n<p>In 2025, the company's overseas revenue reached 840 million yuan, a significant increase of 17.9% year-on-year. This segment's contribution to the company's primary business revenue reached a new high of 36%, up by 5 percentage points from 2024. Growth was observed across all regions: Europe grew by 16.0%, the Asia-Pacific region by 26.0%, the Americas by 12.2%, and Africa by 17.8%.</p>\n<p>Conversely, domestic revenue for 2025 was 1.47 billion yuan, a decline of 5.5% compared to the previous year. Revenue from new industries accounted for 48.5% of the total, with a growth rate of 8.8%. The low-temperature storage industry segment contributed 51.5% of revenue, experiencing a decline of 3.9% year-on-year. Following a return to positive growth in the third quarter, the growth rate accelerated in the fourth quarter, indicating a gradual recovery from the bottom.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Haier Biomedical Reports 31.6% Decline in 2025 Net Profit Attributable to Owners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHaier Biomedical Reports 31.6% Decline in 2025 Net Profit Attributable to Owners\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-27 16:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Qingdao Haier Biomedical Co.,Ltd. (688139.SH) has released its preliminary financial results for the year 2025. The company achieved operating revenue of 2.33 billion yuan, representing a year-on-year increase of 2.0%. However, net profit attributable to owners of the parent company was 250 million yuan, marking a decrease of 31.6% compared to the previous year.</p>\n<p>In 2025, the company's overseas revenue reached 840 million yuan, a significant increase of 17.9% year-on-year. This segment's contribution to the company's primary business revenue reached a new high of 36%, up by 5 percentage points from 2024. Growth was observed across all regions: Europe grew by 16.0%, the Asia-Pacific region by 26.0%, the Americas by 12.2%, and Africa by 17.8%.</p>\n<p>Conversely, domestic revenue for 2025 was 1.47 billion yuan, a decline of 5.5% compared to the previous year. Revenue from new industries accounted for 48.5% of the total, with a growth rate of 8.8%. The low-temperature storage industry segment contributed 51.5% of revenue, experiencing a decline of 3.9% year-on-year. Following a return to positive growth in the third quarter, the growth rate accelerated in the fourth quarter, indicating a gradual recovery from the bottom.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"","article_id":"1107989005","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1107989005","pubTimestamp":1772179822,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Qingdao Haier Biomedical Co.,Ltd. (688139.SH) has released its preliminary financial results for the year 2025. The company achieved operating revenue of 2.33 billion yuan, representing a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688139":"海尔生物","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK0251":"专用设备"},"translate_title":"海尔生物医疗2025年归属于所有者净利润下降31.6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688139":1},"content_text":"Qingdao Haier Biomedical Co.,Ltd. (688139.SH) has released its preliminary financial results for the year 2025. The company achieved operating revenue of 2.33 billion yuan, representing a year-on-year increase of 2.0%. However, net profit attributable to owners of the parent company was 250 million yuan, marking a decrease of 31.6% compared to the previous year.\nIn 2025, the company's overseas revenue reached 840 million yuan, a significant increase of 17.9% year-on-year. This segment's contribution to the company's primary business revenue reached a new high of 36%, up by 5 percentage points from 2024. Growth was observed across all regions: Europe grew by 16.0%, the Asia-Pacific region by 26.0%, the Americas by 12.2%, and Africa by 17.8%.\nConversely, domestic revenue for 2025 was 1.47 billion yuan, a decline of 5.5% compared to the previous year. Revenue from new industries accounted for 48.5% of the total, with a growth rate of 8.8%. The low-temperature storage industry segment contributed 51.5% of revenue, experiencing a decline of 3.9% year-on-year. Following a return to positive growth in the third quarter, the growth rate accelerated in the fourth quarter, indicating a gradual recovery from the bottom.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1107989005","isCrawlerRequest":true}